Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: May, 2017 | Pages:
62 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Lymphocyte Activation Gene 3 Protein (Protein FDC or CD223 or LAG3) - Pipeline Review, H1 2017 Summary Lymphocyte Activation Gene 3 Protein (Protein FDC or CD223 or LAG3) pipeline Target constitutes close to 22 molecules. Out of which approximately 22 molecules are developed by Companies. The latest report Lymphocyte Activation Gene 3 Protein (Protein FDC or CD223 or LAG3) - Pipeline Review, H1 2017, outlays comprehensive information on the Lymphocyte Activation Gene 3 Protein (Protein FDC or CD223 or LAG3) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. Lymphocyte Activation Gene 3 Protein (Protein FDC or CD223 or LAG3) - Lymphocyte-activation gene 3 or LAG-3 is a protein encoded by the LAG3 gene. It is involved in the maturation and activation of dendritic cells and lymphocyte activation. It binds to HLA class-II antigens. The molecules developed by companies in Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 2, 5, 2, 8 and 5 respectively. Report covers products from therapy areas Oncology, Immunology, Cardiovascular and Infectious Disease which include indications Solid Tumor, Non-Small Cell Lung Cancer, Autoimmune Disorders, Lymphoma, Melanoma, Advanced Malignancy, Bladder Cancer, Blood Cancer, Cardiovascular Disease, Cervical Cancer, Chronic Inflammation, Colorectal Cancer, Diffuse Large B-Cell Lymphoma, Follicular Lymphoma, Gastric Cancer, Gliosarcoma, Head And Neck Cancer Squamous Cell Carcinoma, Hepatocellular Carcinoma, Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma), Inflammation, Kidney Cancer (Renal Cell Cancer), Non-Hodgkin Lymphoma, Ovarian Cancer, Plaque Psoriasis (Psoriasis Vulgaris), Recurrent Glioblastoma Multiforme (GBM), Refractory Chronic Lymphocytic Leukemia (CLL), Refractory Multiple Myeloma, Relapsed Chronic Lymphocytic Leukemia (CLL), Relapsed Multiple Myeloma and Renal Cell Carcinoma. Furthermore, this report also reviews key players involved in Lymphocyte Activation Gene 3 Protein (Protein FDC or CD223 or LAG3) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Scope - The report provides a snapshot of the global therapeutic landscape for Lymphocyte Activation Gene 3 Protein (Protein FDC or CD223 or LAG3) - The report reviews Lymphocyte Activation Gene 3 Protein (Protein FDC or CD223 or LAG3)targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in Lymphocyte Activation Gene 3 Protein (Protein FDC or CD223 or LAG3)targeted therapeutics and enlists all their major and minor projects - The report assesses Lymphocyte Activation Gene 3 Protein (Protein FDC or CD223 or LAG3) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type - The report summarizes all the dormant and discontinued pipeline projects - The report reviews latest news and deals related to Lymphocyte Activation Gene 3 Protein (Protein FDC or CD223 or LAG3) targeted therapeutics Reasons to buy - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand the targeted therapy areas and indications for Lymphocyte Activation Gene 3 Protein (Protein FDC or CD223 or LAG3) - Identify the use of drugs for target identification and drug repurposing - Identify potential new clients or partners in the target demographic - Develop strategic initiatives by understanding the focus areas of leading companies - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding Lymphocyte Activation Gene 3 Protein (Protein FDC or CD223 or LAG3)development landscape - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope
Table of Contents
List of Tables List of Figures Introduction Global Markets Direct Report Coverage Lymphocyte Activation Gene 3 Protein (Protein FDC or CD223 or LAG3) - Overview Lymphocyte Activation Gene 3 Protein (Protein FDC or CD223 or LAG3) - Therapeutics Development Products under Development by Stage of Development Products under Development by Therapy Area Products under Development by Indication Products under Development by Companies Lymphocyte Activation Gene 3 Protein (Protein FDC or CD223 or LAG3) - Therapeutics Assessment Assessment by Mechanism of Action Assessment by Route of Administration Assessment by Molecule Type Lymphocyte Activation Gene 3 Protein (Protein FDC or CD223 or LAG3) - Companies Involved in Therapeutics Development Boehringer Ingelheim GmbH Bristol-Myers Squibb Company Crescendo Biologics Ltd Enumeral Biomedical Holdings Inc GlaxoSmithKline Plc Icell Kealex Therapeutics Incyte Corp MacroGenics Inc Merck & Co Inc Novartis AG Prima BioMed Ltd Regeneron Pharmaceuticals Inc Sutro Biopharma Inc Symphogen A/S Tesaro Inc Trellis Bioscience Inc Xencor Inc Lymphocyte Activation Gene 3 Protein (Protein FDC or CD223 or LAG3) - Drug Profiles BI-754111 - Drug Profile Product Description Mechanism Of Action R&D Progress BMS-986016 - Drug Profile Product Description Mechanism Of Action R&D Progress ENUM-006 - Drug Profile Product Description Mechanism Of Action R&D Progress IKT-203 - Drug Profile Product Description Mechanism Of Action R&D Progress IMP-701 - Drug Profile Product Description Mechanism Of Action R&D Progress IMP-731 - Drug Profile Product Description Mechanism Of Action R&D Progress IMP-761 - Drug Profile Product Description Mechanism Of Action R&D Progress LAG-525 - Drug Profile Product Description Mechanism Of Action R&D Progress MGD-013 - Drug Profile Product Description Mechanism Of Action R&D Progress MK-4280 - Drug Profile Product Description Mechanism Of Action R&D Progress Monoclonal Antibody to Inhibit LAG-3 for Oncology - Drug Profile Product Description Mechanism Of Action R&D Progress Monoclonal Antibody to Inhibit LAG3 for Oncology - Drug Profile Product Description Mechanism Of Action R&D Progress Monoclonal Antibody to Inhibit LAG3 for Oncology - Drug Profile Product Description Mechanism Of Action R&D Progress Monoclonal Antibody to Inhibit PD-1 and LAG-3 for Oncology - Drug Profile Product Description Mechanism Of Action R&D Progress Monoclonal Antibody to Target CTLA-4 and LAG-3 for Oncology - Drug Profile Product Description Mechanism Of Action R&D Progress Monoclonal Antibody to Target PD-1 and LAG-3 for Oncology - Drug Profile Product Description Mechanism Of Action R&D Progress Monoclonal Antibody to Target PD-1 and LAG-3 for Oncology - Drug Profile Product Description Mechanism Of Action R&D Progress Recombinant Protein to Replace CD223 for Cardiovascular Disease and Chronic Inflammation - Drug Profile Product Description Mechanism Of Action R&D Progress REGN-2810 + REGN-3767 - Drug Profile Product Description Mechanism Of Action R&D Progress REGN-3767 - Drug Profile Product Description Mechanism Of Action R&D Progress TRL-7117 - Drug Profile Product Description Mechanism Of Action R&D Progress TSR-033 - Drug Profile Product Description Mechanism Of Action R&D Progress Lymphocyte Activation Gene 3 Protein (Protein FDC or CD223 or LAG3) - Dormant Products Lymphocyte Activation Gene 3 Protein (Protein FDC or CD223 or LAG3) - Product Development Milestones Featured News & Press Releases May 01, 2017: TESARO Announces Submission of Investigational New Drug Application for Anti-LAG Antibody TSR-033 to the U.S. FDA Jan 03, 2017: Prima Announces New Product Candidate IMP761 - A LAG-3 Agonist Antibody Aug 25, 2016: European Patent Grants for IMP731 Antibody Apr 19, 2016: MacroGenics Presents Data from MGD013 Preclinical Program at AACR Annual Meeting 2016 Feb 08, 2016: Crescendo Biologics Presents Key Oncology Data on Humabody Drug Conjugates Jan 27, 2016: US Patent Grants for IMP731 Antibody Aug 14, 2015: Prima Biomed Announces Commencement of Milestones for IMP701 Program May 27, 2015: Crescendo Biologics Expands ADC Programmes with Innovate UK Funding Award Appendix Methodology Coverage Secondary Research Primary Research Expert Panel Validation Contact Us Disclaimer
List of Tables
Number of Products under Development by Stage of Development, H1 2017 Number of Products under Development by Therapy Areas, H1 2017 Number of Products under Development by Indications, H1 2017 Number of Products under Development by Indications, H1 2017 (Contd..1), H1 2017 Number of Products under Development by Companies, H1 2017 Products under Development by Companies, H1 2017 Products under Development by Companies, H1 2017 (Contd..1), H1 2017 Products under Development by Companies, H1 2017 (Contd..2), H1 2017 Number of Products by Stage and Mechanism of Actions, H1 2017 Number of Products by Stage and Route of Administration, H1 2017 Number of Products by Stage and Molecule Type, H1 2017 Pipeline by Boehringer Ingelheim GmbH, H1 2017 Pipeline by Bristol-Myers Squibb Company, H1 2017 Pipeline by Crescendo Biologics Ltd, H1 2017 Pipeline by Enumeral Biomedical Holdings Inc, H1 2017 Pipeline by GlaxoSmithKline Plc, H1 2017 Pipeline by Icell Kealex Therapeutics, H1 2017 Pipeline by Incyte Corp, H1 2017 Pipeline by MacroGenics Inc, H1 2017 Pipeline by Merck & Co Inc, H1 2017 Pipeline by Novartis AG, H1 2017 Pipeline by Prima BioMed Ltd, H1 2017 Pipeline by Regeneron Pharmaceuticals Inc, H1 2017 Pipeline by Sutro Biopharma Inc, H1 2017 Pipeline by Symphogen A/S, H1 2017 Pipeline by Tesaro Inc, H1 2017 Pipeline by Trellis Bioscience Inc, H1 2017 Pipeline by Xencor Inc, H1 2017 Dormant Projects, H1 2017
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
